No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KALV KalVista Pharmaceuticals
- 11.500
- -0.150-1.29%
Close Apr 18 16:00 ET
- 11.500
- 0.0000.00%
Post 16:02 ET
485.17MMarket Cap-3685P/E (TTM)
11.750High11.280Low408.66KVolume11.530Open11.650Pre Close4.72MTurnover1.70%Turnover RatioLossP/E (Static)42.19MShares16.88052wk High5.48P/B277.34MFloat Cap7.21052wk Low--Dividend TTM24.12MShs Float129.108Historical High--Div YieldTTM4.03%Amplitude4.120Historical Low11.558Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target
Needham analyst Serge Belanger reiterates KalVista Pharma with a Buy and maintains $35 price target.
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors g
Express News | HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $24 Price Target
Express News | KalVista Pharmaceuticals Announced The UK Medicines And Healthcare Products Regulatory Agency Has Awarded The Promising Innovative Medicine Designation For Sebetralstat For On-demand Treatment Of Hereditary Angioedema
Comments
The recent share sale by the CEO and the absence of insider buying over the past year may raise concerns. The low level of insider ownership compared to most companies is also somewhat worrying. Caution is advised when considering buying KalVista Pharmaceuticals stock.
Have KalVista Pharmaceuticals Insiders Been Selling Stock?
Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Regenxbio(RGNX.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Vertex Pharmaceuticals(VRTX.US$ Phase 3
$KalVista Pharmaceuticals(KALV.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$Applied Therapeutics(APLT.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3...
$Regenxbio(RGNX.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Vertex Pharmaceuticals(VRTX.US$ Phase 3
$KalVista Pharmaceuticals(KALV.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$Applied Therapeutics(APLT.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3...
20
1
The termination of the KVD824 trial may impact KalVista's financials and stock price, but the company remains focused on advancing its other drug, sebetralstat, and its oral Factor XIIa inhibitor program for HAE prophylaxis.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg